Abstract
Nuclear medicine has been i nvolved in the field of functional tumor imaging for decades. Its hallmark is the detection of viable tumor tissue based on functional and biological characteristics rather than on an altered tumor morphology. Scintigraphy has an important role in monitoring the response to therapy, by distinguishing active tumor mass, where the tumor-seeking tracer still accumulates, from residual mass composed of necrosis or scar, where tracer no longer accumulates. The use of scintigraphy in tumor detection depends on the mechanism of tracer uptake in the tumor, the pharmacokinetic and normal biodistribution of the tracer, and on the technology of the detecting system.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fowler AM (2014) A molecular approach to breast imaging. J Nucl Med 55:177–180.
Sun Y, Wei W, Yang HW, Liu JL (2013) Specific gamma imaging as an adjunct modality to mammography for diagnosis of breast cancer: a systemic review and meta-analysis. Eur J Nucl Med Mol Imaging 40:450–463.
Brem RF, Shahan C, Rapleyea JA et al (2010) Detection of occult foci of breast cancer using breast-specific gamma imaging in women with one mammographic or clinically suspicious breast lesion. Acad Radiol 17:735–743.
Hruska CB, Phillips S W, Whaley DH et al (2008) Molecular breast imaging: use of a dual-head dedicated gamma camera to detect small breast tumors. AJR Am J Roentgenol 191:1805–1815.
MacDonald L, Edwards J, Lewellen T et al (2009) Clinical imaging characteristics of the positron emission mammography camera: PEM Flex Solo II. J Nucl Med 50:1666–1675.
Moliner L, Gonzalez AJ, Soriano A et al (2012) Design and evaluation of the MAMMI dedicated breast PET. Med Phys 39:5393–5404.
Kalinya JE, Berg WA, Schilling K et al (2014) Breast cancer detection using high-resolution breast PET compared to whole-body PET or PET/CT. Eur J Nucl Med Mol Imaging 41:260–275.
van Leeuwen FW, Buckle T, Kersbergen A et al (2009) Noninvasive functional imaging of P-glycoprotein-mediated doxorubicin resistance in a mouse model of hereditary breast cancer to predict response, and assign P-gp inhibitor sensitivity. Eur J Nucl Med Mol Imaging 36:406–412
Vecchio SD, Zannetti A, Salvatore B et al (2006) Functional imaging of multidrug resistance in breast cancer. Phys Med 21(Suppl 1):24–27.
Koolen BB, Vrancken Peeters MJ, Wesseling J et al (2012) Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 39:1830–1838.
Ekmekcioglu O, Aliyev A, Yilmaz S et al (2013) Correlation of 18F-fluorodeoxyglucose uptake with histopathological prognostic factors in breast carcinoma. Nucl Med Commun 34:1055–1067.
Buck A, Schirrmeister H, Kühn T et al (2002) FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 29:1317–1323.
Koolen BB, Vidal-Sicart S, Benlloch Baviera JM, Valdés Olmos RA (2014) Evaluating heterogeneity of primary tumor (18)F-FDG uptake in breast cancer with a dedicated breast PET (MAMMI): a feasibility study based on correlation with PET/CT. Nucl Med Commun 35:446–452.
Brem RF, Ioffe M, Rapelyea JA et al (2009) Invasive lobular carcinoma: detection with mammography sonography MRI, and breast-specific gamma imaging. AJR Am J Roentgenol 192:379–383.
Rhodes DJ, Hruska CB, Phillips SW et al (2011) Dedicated dual-head gamma imaging for breast cancer screening in women with mammographically dense breasts. Radiology 258:106–118.
Berg WA, Madsen KS, Schilling K et al (2011) Breast cancer: comparative effectiveness of positron emission mammography and MR imaging in presurgical planning for the ipsilateral breast. Radiology 258:59–72.
Berg WA1, Madsen KS, Schilling K et al (2012) Comparative effectiveness of positron emission mammography and MRI in the contralateral breast of women with newly diagnosed breast cancer. AJR Am J Roentgenol 198:219–232.
Dunnwald LK, Gralow JR, Ellis GK et al (2005) Residual tumor uptake of [99mTc]-sestaMIBI after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival. Cancer 103:680–688.
Mitchell D1, Hruska CB, Boughey JC et al (2013) 99mTc-sestaMIBI using a direct conversion molecular breast imaging system to assess tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer. Clin Nucl Med 38:949–956.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Italia
About this chapter
Cite this chapter
Even-Sapir, E. (2015). Scintimammography. In: Hodler, J., von Schulthess, G.K., Kubik-Huch, R.A., Zollikofer, C.L. (eds) Diseases of the Chest and Heart 2015–2018. Springer, Milano. https://doi.org/10.1007/978-88-470-5752-4_33
Download citation
DOI: https://doi.org/10.1007/978-88-470-5752-4_33
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-5751-7
Online ISBN: 978-88-470-5752-4
eBook Packages: MedicineMedicine (R0)